AXT (AXTI) Q2 Revenue Drops 36%

AXT reported a significant Q2 2025 financial miss, with GAAP revenue of $18.0 million falling 9.0% below estimates and non-GAAP loss per share widening to ($0.15) against expectations of ($0.13). This underperformance stemmed from soft demand, particularly in China, and regulatory delays impacting export permits. While non-GAAP gross margin sequentially improved to 8.2%, it remained sharply down year-over-year. Despite a positive trend in indium phosphide (InP) substrate shipments for AI applications, these gains were insufficient to offset broader market weakness and persistent geopolitical challenges, notably the unresolved STAR Market IPO of its Chinese subsidiary.

Analysis

AXT Inc. reported a significant Q2 2025 miss, with GAAP revenue of $18.0 million falling 9.0% short of the $19.78 million consensus estimate and representing a steep 35.5% year-over-year decline. The non-GAAP loss per share widened to ($0.15), missing expectations of ($0.13) and marking a severe deterioration from the ($0.02) loss in the prior-year quarter. Management attributed this underperformance primarily to a sluggish demand environment in China and prolonged processing times for gallium arsenide export permits, which impacted sales volume. While the non-GAAP gross margin showed a sequential recovery to 8.2% from negative territory in Q1, it remains severely compressed compared to 27.6% in Q2 2024, indicating that internal operational improvements are being negated by low factory utilization. A notable, albeit small, positive development was the increased demand for indium phosphide (InP) substrates driven by artificial intelligence applications; however, this was insufficient to offset the broad-based weakness. Persistent uncertainty surrounding the company’s regulatory environment, including the unresolved STAR Market IPO for its Chinese subsidiary Tongmei, continues to present a significant overhang on the business.

Key Decisions for Investors

• Investors should closely monitor the status of Chinese export permits and any progress on the Tongmei STAR Market IPO, as these regulatory factors are primary drivers of the current revenue shortfalls and valuation uncertainty.
• Given the severe year-over-year margin contraction, focus on sequential improvements in gross margin and operating cash flow as key indicators of a potential operational turnaround, even ahead of a significant revenue recovery.
• While the growth in AI-related indium phosphide (InP) demand presents a compelling long-term catalyst, its current scale is insufficient to offset near-term headwinds, warranting a cautious assessment of its immediate impact on financials.
• Considering the lack of formal guidance, the sharp revenue decline, and ongoing geopolitical risks, investors may consider maintaining an underweight position until there is tangible evidence of demand stabilization in core markets and a clearer path through regulatory hurdles.